- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Mark Stejbach, Merck
S
Mark Stejbach
VP, Managed Care Marketing, Merck
DOUBLE DUTY: Is helping build Merck's new healthcare model
OF NOTE: First non-finance person to run Merck's investor relations
On payers:
For many years, the success of the industry was at least in part driven by the inefficiency of the economic model of healthcare. In the short term, there's always more to be eked out from the current model—and I think some companies are going to run with that as hard and as long as they can. But in the long term, companies have to understand that the market is going to be increasingly influenced by the people who pay the bills—payers and consumers. In that way, pharma will start to become more like most other industries.
Mark Stejbach
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
